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ed February 11, 2014.he study undertook a systematic review to establish and compare the risk of stroke between the 2 widely used
approaches (transfemoral [TF] vs. transapical [TA]) and valve designs (CoreValve, Medtronic, Minneapolis, Minnesota
vs. Edwards Valve, Edwards Lifesciences, Irvine, California) for transcatheter aortic valve replacement (TAVR).Background There has been a rapid adoption and expansion in the use of TAVR. The technique is however far from perfect and
requires further reﬁnement to alleviate safety concerns that include stroke.Methods All studies reporting on the risk of stroke after TAVR were identiﬁed using an electronic search and pooled using
established meta-analytical guidelines.Results 25 multicenter registries and 33 single-center studies were included in the analysis. There was no difference in
pooled 30-day stroke post-TAVR between the TF and TA approach in multicenter (2.8% [95% conﬁdence interval (CI):
2.4 to 3.4] vs. 2.8% [95% CI: 2.0 to 3.9]) and single-center studies (3.8% [95% CI: 3.1 to 4.6] vs. 3.4% [95% CI: 2.5
to 4.5]). Similarly, there was no difference in pooled 30-day stroke post TAVR between the CoreValve and Edwards
Valve in multicenter (2.4% [95% CI: 1.9 to 3.2] vs. 3.0% [95% CI: 2.4 to 3.7]) and single-center studies (3.8% [95%
CI: 2.8 to 4.9] vs. 3.2% [95% CI: 2.4 to 4.3]). There was a decline in stroke risk with experience and technological
advancement. There was no difference in the outcome of 30-day stroke between TAVR and surgical aortic valve
replacement.Conclusions Our ﬁndings suggest that the risk of 30-day stroke after TAVR is similar between the approaches and valve types.
There has been a decline in stroke risk after TAVR with improvements in valve technology, patient selection, and
operator experience. (J Am Coll Cardiol 2014;63:2101–10) ª 2014 by the American College of Cardiology
FoundationTranscatheter aortic valve replacement (TAVR) has seen an
exponential utilization in high surgical risk patients and an
expansion to the intermediate risk population (1,2) due to
impressive results in randomized PARTNER (Placement of
AoRTic TraNscathetER Valve Trial) (Online Refs.
e18,e19). Despite the growth, TAVR as a procedure is
still evolving and requires further reﬁnement to reduce
complications. Stroke remains a major concern after TAVRlar Medicine, Heart & Vascular Institute, Case
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2013; revised manuscript received February 9,and an important cause of increased morbidity and mortal-
ity. In the PARTNER trial cohort A and cohort B (Online
Refs. e18,e19), the occurrence of stroke was doubled in the
TAVR arm when compared to surgery (4.6% vs. 2.4%) and
medical therapy (6.7% vs. 1.7%), respectively. Similarly, the
risk of stroke in the TAVR arm of the PARTNER trials was
also higher than that reported in the surgical literature for
isolated aortic valve replacement (1.5% to 4%), raising safety
concerns (3,4).
An understanding of the mechanisms underlying stroke
after TAVR is therefore essential for the implementation
of appropriate preventive measures prior to further ex-
pansion in its utilization. The manipulation of bulky
endovascular devices along the aortic arch and aortic root
during the transfemoral (TF) approach and manipulation
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2102of the apex during the transapical
(TA) approach have been impli-
cated for embolic strokes (5,6).
Similarly, difference in valve
design and deliverability between
the self-expanding CoreValve,
Medtronic, Minneapolis, Min-
nesota, and balloon expanding
Edwards Valve, Edwards Life-
sciences, Irvine, California have
also been speculated to alter the
stroke risk after TAVR (5)
(Online Ref. e100). However,
neither of these theories re-
garding valve delivery or valvetype has been conclusively shown to alter risk of stroke after
TAVR. Therefore, we undertook a comprehensive meta-
analysis ﬁrstly, to establish and compare the risk of stroke
between the 2 widely used valves (CoreValve vs. Edwards
Valve) and approaches (TF vs. TA) for TAVR. Second, we
looked at the temporal trend in stroke risk with experience
and advancement in valve technology. Third, we compared
the risk of stroke between TAVR and surgical aortic valve
replacement (SAVR) in matched patient cohorts.Methods
Study selection. We conducted this systematic review on
published literature of stroke following TAVR using the
QUOROM (Quality of Reporting of Meta Analysis) (7)
and MOOSE (Meta Analysis of Observational Studies in
Epidemiology) guidelines (8). A computerized search was
performed to identify all relevant studies published until
July 2013 in the PubMed database by 2 reviewers (G.A.
and D.G.). The following search terms were used: TAVI,
Percutaneous Valves, Transcutaneous Aortic Valve, and
Transcatheter Aortic Valve. Citations were screened at the
title and abstract level and retrieved as a full report if they
reported on outcome of stroke after TAVR. Limiting the
search parameters to the English language was applied
subsequently. The full texts and bibliography of all potential
articles were further reviewed in detail (G.A.) to seek
additional relevant studies. Major conference proceedings
were also searched to retrieve unpublished studies until
November 2013.
Full text and references of all identiﬁed potential publi-
cations and conference proceedings were searched to select
the reports for inclusion in the secondary analysis.
Inclusion criteria. Studies were included if the following
criteria applied: 1) enrollment for TAVR was based on
existing and accepted guidelines; 2) enrolled consecutive
patients; 3) reported data on stroke following TAVR using a
particular approach or valve design; and 4) performed a
minimum of 75 successful TAVR procedures and at least
50 by a particular approach or valve type when from a
single center. When 2 similar studies were reported fromthe same institution or author, the most recent publication
or the publication with most information on stroke post
TAVR was included in the analysis.
Exclusion criteria. Studies were excluded if any of the
following criteria applied: 1) duplicate publication, overlap of
patients, subgroup studies (nonconsecutive) of a main study;
2) lack of data on stroke by a particular approach or valve
design; 3) if a valve other than the CoreValve or Edwards
Valve was used; 4) if they were studies on valve in valve
procedure; and 5) non-English reports.
Data extraction. Relevant information was collected by
G.A./D.G. and included, but was not limited to, ﬁrst
author, year and journal of publication, study design, in-
clusion exclusion criteria, deﬁnition of stroke/transient
ischemic attack, number of subjects included, subjects un-
dergoing successful TAVR, type of device and approach
used, study population demographics, follow up time period
and primary and secondary outcomes.
Study endpoints. The primary end points evaluated were:
1) 30-day risk of stroke after TF and TA approaches; and 2)
30-day risk of stroke after CoreValve and Edwards Valve
implantation. The results were stratiﬁed into single-center
or multicenter experience. Secondary end points of inter-
est were: 30-day risk of stroke after: 1) TAVR feasibility
studies; 2) early TAVR experience vs. overall experience of
large volume centers; and 3) TAVR vs. SAVR.
Deﬁnitions. 30-DAY STROKE. For the purpose of the cur-
rent analysis, we used the following: 1) study-reported
30-day stroke when available; 2) in-hospital/procedural
stroke when 30-day stroke was not available; and 3) com-
bined major and minor stroke if reported separately.
The deﬁnition of stroke was as reported by the primary
study.
FEASIBILITY STUDIES. Represent the initial studies prior to
European Conformite Europeenne approval for the partic-
ular valve design.
HIGH-VOLUME CENTERS. Centers that had performed 100 or
more TAVR procedure for a particular valve/approach.
EARLY EXPERIENCE OF HIGH-VOLUME CENTERS. The ﬁrst
30% to 50% (or closest available) of patients enrolled by a
center for a particular approach or valve design.
Statistical analysis. DerSimonian and Laird’s (9) ran-
dom effects model was utilized to pool the estimates of 30-day
stroke from individual studies and subgroups. A random-
effects model was also used to obtain a single pooled esti-
mate of the odds ratios. The effect across subgroups
was compared using a Q test based on analysis of variance.
Statistical signiﬁcance was set at a p value <0.05 (2-tailed).
Heterogeneity, which was anticipated to be signiﬁcant,
was assessed by a Q statistic and I2 test. Signiﬁcant
heterogeneity was considered present for p values <0.10
and/or an I2 ¼ >50%. Sensitivity analysis was performed
by excluding reports that did not use the Valve Academic
Research Consortium proposed endpoints/deﬁnitions.
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2103Sensitivity analysis was also performed by comparing
30-day risk of stroke by comparing the valve designs for
the TF approach and comparing the type of approach
for the Edwards Valve. Data analysis was performed using
Comprehensive Meta-Analysis Software Version 2 (10).Results
By using the search keywords 6,922 reports were identiﬁed
and reviewed at title and abstract level. Initial evaluation
identiﬁed 1050 publications that were further evaluated
using the search term stroke. This narrowed the selection
to 346 potential publications. Search of conference pro-
ceedings further identiﬁed 15 relevant publications. When
the inclusion and exclusion criteria were applied 25 multi-
center studies (Online Table 1) and 33 single-center pub-
lications (Online Table 2) remained for assessment of the
primary outcomes (Fig. 1). This included 3 randomized
comparisons (Online Refs. e18–e20). All the studies
included in the analysis were published between 2006 and
2013. Analysis was performed on 29,065 patients from
multicenter registries and on 7,149 patients from single-
center studies. Selected Baseline characteristics of the
included patients are summarized in Online Tables 3 and 4.
The VARC criteria were used to report endpoints by 13
and 23 multicenter and single-center studies, respectively
(Online Tables 5 and 6).Figure 1 Flow Chart Depicting the Selection Process
ES ¼ Edwards Valve; MC ¼ Medtronic CoreValve; TA ¼ transapical; TAVI ¼ transcatheteSearching the full text and references of the previous
publications and conference proceedings identiﬁed 12 feasi-
bility studies on 992 patients (Online Table 7), 14 high-
volume centers reporting on early and late experience
(Online Table 8) and 11 reports comparing TAVR and
SAVR in a randomized/matched patient population
(Online Table 9).
Multicenter registries. The TF approach was used in
18,712 patients and the TA approach in 5,650 patients. The
pooled estimate for overall incidence of 30-day stroke
(Fig. 2A) in multicenter registries using the TF approach
was 2.8% (95% CI: 2.4 to 3.4, I2 ¼ 70.14) and that using the
TA approach was 2.8% (95% CI: 2.0 to 3.9, I2 ¼ 68.35).
The VARC proposed deﬁnitions/endpoints were used in
12 registries reporting on the TF approach and by 4 regis-
tries reporting on the TA approach. There was no difference
in stroke in comparing the 2 approaches in sensitivity
analysis (Table 1). Nine multicenter registries involving
14,296 patients compared both approaches (66.9% TF and
33.1% TA). The pooled odds ratio (OR) for in-hospital/
30-day stroke did not reach statistical signiﬁcance (OR:
1.04, 95% CI: 0.83 to 1.31) (Fig. 2B). Similar results were
obtained on sensitivity analysis (Table 1).
The self-expanding MC was implanted in 8,684 pa-
tients and the balloon expandable ES in 16,082 patients.
The pooled estimate for overall incidence of 30-day
stroke (Fig. 3A) in multicenter registries using the MCr aortic valve implantation; TF ¼ transfemoral.
Figure 2 Forest Plot of Multicenter Experience
(A) Showing the individual and pooled event rates for stroke (30-day/in-hospital) using the transfemoral (TF) and transapical (TA) approach for transcatheter aortic valve
replacement (TAVR). (B) Showing the odds ratio for stroke, comparing the TF and TA approach. 18F EE ¼ Expanded evaluation; ADVANCE¼ ADVANCE CoreValve Registry; ANZ¼
Australia & New Zealand; EORP/TCVT ¼ Transcatheter Valve Treatment Sentinel Registry (TCVT) of the EUR Observational Research Programme (EORP); GARY ¼ German Aortic
Valve Registry; I-TA¼ Italian transapical Registry; PREVAIL¼ PREVAIL TRANSAPICAL; SOURCE¼ SOURCE Registry; STS/ACC TVT ¼ STS/ACC TVT Registry; TAVI¼ transcatheter
aortic valve implantation.
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2104valve was 2.4% (95% CI: 1.9 to 3.2, I2 ¼ 64.28) and that
using the Edwards Valve was 3.0% (95% CI: 2.4 to 3.7,
I2 ¼ 73.89). The VARC proposed deﬁnitions/endpointswere used in 8 registries reporting on the MC valve and
by 8 registries reporting on the ES. Therewas nodifference in
stroke on comparing the 2 valves (Table 1). Seven multicenter
Table 1
Risk of Stroke After Transcatheter Aortic Valve




Transfemoral approach, % 2.4 (1.9–3.0)
Transapical approach, % 1.8 (1.1–2.8)
Transfemoral versus transapical approach 1.14 (0.75–1.74)
Single-center experience
Transfemoral approach, % 3.9 (3.2–4.8)
Transapical approach, % 3.2 (2.2–4.8)
Transfemoral versus transapical approach 1.06 (0.61–1.85)
Multicenter experience
CoreValve, % 2.2 (1.6–3.1)
Edwards Valve, % 2.5 (1.8–3.4)
CoreValve versus Edwards Valve 1.10 (0.79–1.51)
Single-center experience
CoreValve, % 4.1 (3.1–5.4)
Edwards Valve, % 3.0 (2.1–4.3)
CoreValve versus Edwards Valve 1.28 (0.43–3.81)
VARC ¼ Valve Academic Research Consortium.
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2105registries involving 8,758 patients compared both valves (41%
MC and 59% ES). The pooled OR for in-hospital/30-day
stroke (MC vs. ES) did not reach statistical signiﬁcance (OR:
1.03, 95% CI: 0.78 to 1.35) (Fig. 3B). Similar results were
obtained on sensitivity analysis (Table 1).
Single-center studies. The TF approach was used in
4,556 patients and the TA approach in 2,588 patients. The
pooled estimate for overall incidence of 30-day stroke
(Online Fig. 1A) in single-center studies using the TF
approach was 3.8% (95% CI: 3.1 to 4.6, I2 ¼ 34.24) and that
using the TA approach was 3.4% (95% CI: 2.5 to 4.5,
I2 ¼ 35.36). The VARC proposed deﬁnitions/endpoints
were used by 22 centers for reporting outcomes on the TF
approach and by 9 centers for reporting outcomes on the TA
approach. There was no difference in stroke on comparing
the 2 approaches (Table 1). Nine reports involving 2,448
patients compared both approaches (61.3% TF and 38.7%
TA). The pooled OR for in-hospital/30-day stroke did not
reach statistical signiﬁcance (OR: 1.16, 95% CI: 0.72 to
1.85) (Online Fig. 1B). Similar results were obtained on
sensitivity analysis (Table 1).
The self-expanding MC was implanted in 2,617 patients
and the balloon expandable ES in 3,477 patients. The
pooled estimate for overall incidence of 30-day stroke
(Online Fig. 2A) in single-center studies using the MC
valve was 3.8% (95% CI: 2.8 to 4.9, I2 ¼ 35.71) and that
using the ES was 3.2% (95% CI: 2.4 to 4.3, I2 ¼ 49.27).
The VARC proposed deﬁnitions/endpoints were used by
12 single-centers reporting on the MC valve and by 12
single centers reporting on the ES. There was no difference
in stroke on comparing the 2 valves (Table 1). Five reports
involving 1,429 patients compared both valves (59.34%
MC and 40.6% ES). The pooled OR for in-hospital/30-
day stroke (Medtronic CoreValve vs. Edwards Valve) didnot reach statistical signiﬁcance (OR: 1.81, 95% CI: 0.69 to
4.74) (Online Fig. 2B). Similar results were obtained on
sensitivity analysis (Table 1).
Feasibility studies and early experience of high-volume
centers. There were 14 feasibility studies that enrolled a
total of 992 patients, 7 using the TF approach (521 patients)
and 7 using the TA approach (471 patients). The pooled
estimate for overall incidence of 30-day stroke in feasibility
studies using the TF approach was 7.1% (95% CI: 5.0 to 10,
I2 ¼ 10.75) and that using the TA approach was 2.6% (95%
CI: 1.4 to 4.5, I2 ¼ 0.00). There was a signiﬁcant increase
in the risk of stroke (Fig. 4A) with use of the TF approach
(p ¼ 0.003). The risk of stroke using the TF approach was
higher than that seen in contemporary studies (7.1% vs.
2.9%). There was a progressive decline with gaining expe-
rience in the incidence of stroke after TAVR (Fig. 4B).
We identiﬁed 14 high-volume TAVR centers reporting
on 3,813 TAVR procedures (9 centers for the TF approach
and 5 centers for the TA approach). In high-volume centers
the overall odds of 30-day stroke using the TF approach
(Fig. 5A) in the early experience was 4.9% (95% CI: 3.6 to
6.6) and that in the overall experience was 3.4% (95% CI:
2.6 to 4.6). The overall odds of 30-day stroke using the TA
(Fig. 5B) approach in the early experience from high-volume
centers was 1.8% (95% CI: 0.8 to 4.4) and that in the overall
experience was 2.8% (95% CI: 1.9 to 4.3).
TAVR versus SAVR. Eleven reports that included 2
randomized control trials and 9 propensity-matched an-
alyses reported on patients. There was no difference in the
risk of stroke between the 2 approaches in both high-risk
(OR: 1.24, 95% CI: 0.58 to 2.65, I2 ¼ 13.83) and
intermediate-risk patients (OR: 1.69, 95% CI: 0.33 to 8.48,
I2 ¼ 33.69). The pooled OR for in-hospital/30-day stroke
(TAVR vs. SAVR) did not reach statistical signiﬁcance for
both comparisons (Online Figs. 3A and 3B).
Subgroup analysis of Edwards Valve. We performed a
subgroup analysis to compare the valve designs exclusively
for the femoral approach (Online Fig. 4) . There was no
difference between the Edwards valve and CoreValve for
30-day stroke post-TAVR in both multicenter (3.0% vs.
2.3%, p ¼ 0.17) and single-center studies (4.4% vs. 3.9%,
p ¼ 0.7). We also compared the 30-day stroke between the
2 approaches (TF and TA) exclusively with use of the
Edwards valve (Online Fig. 5). There was again no differ-
ence in 30-day stroke post-TAVR with either approach in
both multicenter (3.2% vs. 2.8%, p ¼ 0.49) and single-
center studies (4.2% vs. 3.4%, p ¼ 0.44).
Discussion
TAVR was introduced as a revolutionary treatment option
for inoperable patients with severe aortic stenosis in 2002
(11). It has since shown comparable results to SAVR,
rapidly evolved with more than 150,000 procedures per-
formed worldwide and has seen an expansion of its in-
dications. Expansion in utilization and indications has
Figure 3 Forest Plot of Multicenter Experience
(A) Showing the individual and pooled event rates for stroke (30-day/in-hospital) using the CoreValve (TF) or Edwards Valve (ES) for TAVR. (B) Showing the odds ratio for stroke,
comparing the CoreValve and Edwards Valve. ES ¼ Edwards Valve; MC ¼ Medtronic CoreValve; other abbreviations as in Figure 2.
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safety. In the PARTNER trial cohort B (Online Ref. e19),
comparing TAVR to medical therapy, neurological events
occurred more frequently with TAVR at 30 days (6.7% to
1.7%, p ¼ 0.03). A similar trend was noticed in cohort A
(Online Ref. e18) patients of the PARTNER trial
comparing TAVR to SAVR (4.6% vs. 2.4%). An analysis of
the Society of Thoracic Surgeons database of patients un-
dergoing isolated aortic valve replacement between 2002 and2006 showed a 1.6% risk of stroke (3). Others have reported
a stroke rate in the order of 0.8% to 5% for SAVR compared
to 0% to 10% for TAVR (4). Stroke has thus surfaced as
a major safety concern after TAVR. Of note though, there
is a lack of consistent deﬁnitions and inconsistencies in
surveillance and reporting standards across the reports pre-
cluding any ﬁrm conclusions. Nevertheless, there does
appear to be a risk of stroke with TAVR that has a potential
for further improvement as we advance.
Figure 4 Forest Plot of Feasibility Study Experience
(A) Showing the individual and pooled event rates for stroke (30-day/in-hospital) using the TF and TA approach for TAVR. (B) Showing the cumulative risk of stroke after TAVR
with gaining experience. REVIVAL ¼ TRanscatheter EndoVascular Implantation of VALves trial, REVIVE ¼ Registry of Endovascular Implantation of Valves in Europe; TRAVERCE¼
Trial for trans-apical aortic-valve implantation; other abbreviations as in Figure 2.
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approach in most centers worldwide. It involves the
advancement of a delivery catheter containing the valve from
the common femoral artery to the ascending aorta, a course
that traverses the aortic arch and origins of the carotids, with
a potential for cerebral embolism of atherosclerotic aortic
plaques. On the other hand, the TA approach allows direct
access to the aortic valve via the left ventricular apex
bypassing the aortic arch and the origin of the carotids. Theretrograde approach further requires crossing of the stenotic
aortic valve with a guide wire that may increase the risk of
stroke. There are likewise suggestions that valve sizing,
positioning, and implantation may be better with a TA
approach with subsequent reduction in paravalvular leak and
balloon post-dilation, need for repositioning, and shorter
ﬂuoroscopic time, factors that have been linked to neuro-
logical events after TAVR (12) (Online Refs.
e99,e100,e104). An earlier meta-analysis on 7,541 patients
Figure 5 Forest Plot of High-Volume Center Experience
(A) Showing the individual and pooled event rates for stroke (30-day/in-hospital) using the transfemoral (TF) approach in the early and overall patient pool. (B) Showing
the individual and pooled event rates for stroke (30-day/in-hospital) using the transapical (TA) approach in the early and overall patient pool. CI ¼ conﬁdence interval;
TAVR ¼ transcatheter aortic valve replacement.
Athappan et al. JACC Vol. 63, No. 20, 2014
Stroke After TAVR: Influence of TAVR Strategy and Valve Design May 27, 2014:2101–10
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approach was associated with a 2.7% risk of stroke, as
opposed to 3.1% for the TF approach using the CoreValve
and 4.2% using the Edwards Valve. This ﬁnding has how-
ever not borne out because with subsequent reports sug-
gesting a similar risk of stroke unrelated to the chosen
approach (Online Refs. e23,e100). In our analysis, the stroke
risk was comparable between the 2 approaches, in large
multicenter (2.8% vs. 2.8%) and single-center studies (3.8%
vs. 3.4%). This is in parallel to etiological studies of stroke
with TAVR that suggest a high-risk period during balloon
pre-dilation, valve positioning, and implantation (crushing
of the stenotic native valve) factors common to both ap-
proaches and not during catheter manipulation across the
aortic arch (Online Refs. e104–e106,e112). Therefore, it issafe to conclude that the major source of atherosclerotic
emboli during TAVR is from aortic root manipulation
and much less or negligible from arch manipulation. A
point to be remembered is that catheter manipulation,
though decreased with the TA approach is not fully
eliminated.
The CoreValve and the Edwards valve are the most ex-
tensively evaluated valves for TAVR thus far, with important
differences in design, deliverability and implantation
technique that have been speculated to inﬂuence the risk of
stroke. Eggebrecht et al. (5) in a pooled analysis of 5,097
patients implied a higher stroke with the Edwards valve
when compared to the CoreValve (4.2% vs. 3.1%). Others
have suggested a trend toward a higher risk of stroke with
the CoreValve (3.5% vs. 1.5%) (13). In our pooled analysis
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(multicenter registries, OR: 1.03; 95% CI: 0.78 to 1.35; and
single-center studies, OR: 1.81; 95% CI: 0.69 to 4.74).
Despite the similar stroke risk there may be an important
differences in timing of stroke inherent to each valve, an
understanding of which may be crucial in developing future
valve designs to reduce stroke. Keeping with the high-risk
period of stroke during positioning and valve deployment,
Kahlert et al. (Online Ref. e112) showed that the risk with
the CoreValve is during the slow stepwise implantation,
while that with the Edwards valve, it is during the slow
positioning of the device prior to implantation. Valve
dislocation and embolization are more commonly reported
with the CoreValve (14). Strategies to manage these com-
plications are well known to increase periprocedural stroke
(15) (Online Ref. e100). Rapid pacing during implantation
of the Edwards valve is crucial for accurate positioning un-
like that for the CoreValve. Rapid pacing causes functional
cardiac arrest with ensuing transient cerebral ischemia that
may be linked to clinical stroke (Online Ref. e107). Balloon
post-dilation to reduce paravalvular leak is a common
practice with both valve designs. It has been linked to stroke
(Online Refs. e100,e113) and should be avoided where
possible, balancing the risk of mortality with even mild
aortic insufﬁciency (16).
The risk of stroke has declined over the years with
operator experience, advancements in valve technology, and
improvement in patient selection. In the PARTNER trial
(Online Refs. e18,e19) all patients received an Edwards
SAPIEN device using a 22- to 24-F delivery catheter. The
current generation CoreValve and SAPIEN XT valve use
an 18-F delivery catheter and have a lower proﬁle. In the
PARTNER II trial (Online Ref. e20) the 30-day risk of
stroke was 3.2% with use of the Sapien XT device compared
to a 5.5% to 6.7% risk in the PARTNER I trial. Similarly,
the risk of stroke in the CoreValve ADVANCE study
(Online Ref. e3) that included over 1,000 patients was only
2.9%. Comparing the pooled, early versus late experience of
high-volume centers, we found a comparable drop in stroke
risk (4.9% vs. 3.4%). Along the same lines, the risk of stroke
after TAVR as compared to SAVR has declined. The cur-
rent risk is within the range reported by historical SAVR
trials (3,4). It must however be pointed out that none of the
historical surgical trials were scrutinized as closely as TAVR,
and therefore the true stroke risk after SAVR may be under-
represented.
There is growing interest in embolic protection ﬁlters to
further reduce the risk of stroke after TAVR. In a cohort of
40 patients who underwent TAVR with use of an embolic
protection device, Van Mieghem et al. (17) showed that
embolic debris was captured by the ﬁlter in 75% of the
procedures. The captured emboli consisted of both tissue
fragments and thrombotic debris. The potential of embolic
protection devices to clinically impact outcomes is currently
under investigation, as stroke after TAVR is multifactorial
with the risk prevalent at all steps of the procedure andalso beyond (Online Table 10). Approximately 50% to
60% of strokes occur within 24 h and the majority of the
rest within a week of the procedure (18,19). Furthermore,
progressive device iterations, improved patient selection,
and advancing operator experience are continually de-
creasing the risk of procedural stroke. Attention to
antithrombotic therapies and risk factors beyond the pro-
cedure may also be rewarding.
Moving forward, uniform prospective surveillance and
reporting of stroke per the VARC2 criteria (20) will deﬁne
the true stroke burden after TAVR and enable valid in-
terpretations and comparison across trials. Of concern
though is the reliance on neuroimaging to detect stroke.
Clinically silent new ischemic brain lesions are relatively
common after TAVR on diffusion-weighted cerebral mag-
netic resonance imaging studies (21). Supplanting a
comprehensive neurological examination with neuro-
imaging will therefore likely overinﬂate the risk of stroke
after TAVR. Imperative to accurate stroke identiﬁcation
is anatomical localization by sound neurological exami-
nation in order to identify clinically relevant lesions. Pre-
imaging localization by clinical exam should be stressed
and incorporated in the VARC2 recommendations to
precisely identify strokes in the TAVR population.
Clinical exam should not be replaced by imaging.
Study limitations. First, publication bias is an important
limitation of our analysis. Data from included studies and
registries may be outdated as the true utilization of TAVR is
not matched by the pace of reporting. Also, single-center
studies that were excluded because of low volumes are
most likely to have progressed to high volumes. Second,
there were no randomized comparisons between the ap-
proaches (TF or TA) or valve designs (MC vs. ES). This
introduced signiﬁcant heterogeneity. Third, the deﬁnition
of stroke was variable within the included reports, as was
surveillance and reporting. Minor stroke is likely under-
represented in our analysis. Nevertheless, despite these
limitations our analysis on >25,000 patients is the largest
sampling to date and thus provides valuable insights into the
risk of stroke post-TAVR.
Conclusions
In this large meta-analysis there was no difference in stroke
between the approach (TF or TA) or type of valve (MC or
ES) used for TAVR. Importantly, there was a decline in
stroke over time, reﬂecting on continually improving out-
comes after TAVR. Reduction in device proﬁles over time
and advancements in technique are likely to make TAVR
safe, to potentially expand its indications to a low-risk
population.
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